Theravance Biopharma
- Country
- Ownership
- -
- Employees
- 99
- Market Cap
- -
- Introduction
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded i...
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 102
- Registration Number
- NCT05696717
- Locations
- 🇺🇸
TBPH Investigative Site, Boston, Massachusetts, United States
🇫🇷Centre d'Investigation Clinique Hôpital Pierre Paul Rique, Toulouse, France
🇺🇸Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
- Conditions
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 404
- Registration Number
- NCT05165485
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site site 2, Clearwater, Florida, United States
🇺🇸Theravance Biopharma Investigational Site, Cudahy, Wisconsin, United States
🇺🇸Theravance Biopharma Investigational Site #2, Spartanburg, South Carolina, United States
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 14
- Registration Number
- NCT05091723
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Cypress, California, United States
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 72
- Registration Number
- NCT04688632
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Tempe, Arizona, United States
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 14
- Registration Number
- NCT04681079
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Kansas City, Kansas, United States
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 72
- Registration Number
- NCT04589260
- Locations
- 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 58
- Registration Number
- NCT04587713
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Lincoln, Nebraska, United States
TD-0903 for ALI Associated With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 235
- Registration Number
- NCT04402866
- Locations
- 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom
🇺🇸Theravance Biopharma, Hyde Park, New York, United States
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 54
- Registration Number
- NCT04350736
- Locations
- 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 31
- Registration Number
- NCT04200573
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Orlando, Florida, United States